Repligen Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Repligen Corp 公司

Repligen Corporation 是一家全球生命科學公司，致力於開發和商業化生物加工技術和系統。其重點領域是過濾和流體管理、色譜、過程分析和蛋白質。其過濾產品用於工藝開發和工藝規模（臨牀和商業）生產。其 XCell ATF 系統用於上游灌注（連續）和 N-1（強化補料分批或混合灌注）細胞培養處理。其色譜特許經營包括用於生物藥物下游純化、開發、製造和質量控制的多種產品。其過程分析產品補充並支持其過濾、色譜和蛋白質特許經營。其 TangenX 產品組合包括主要用於下游和超濾過程的平板 (FS) 切向流過濾 (TFF) 盒。其桌面產品組合包括 MAVERICK 和 MAVEN、REBEL 和 ZipChip。

Repligen Corp簡介



公司代碼RGEN

公司名稱Repligen Corp

上市日期Apr 29, 1986

CEOMr. Olivier Loeillot

員工數量1778

證券類型Ordinary Share

年結日Apr 29

公司地址Building 1, Suite 100

城市WALTHAM

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02453

電話17814499560

網址https://www.repligen.com/

公司代碼RGEN

上市日期Apr 29, 1986

CEOMr. Olivier Loeillot

Repligen Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

--

Mr. Jason K. Garland

Chief Financial Officer

--

Mr. Tony John Hunt

Executive Chairman of the Board

--

Dr. Martin D. Madaus, Ph.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

暫無數據

地區USD

名稱

營收

佔比

North America

89.36M

49.00%

Europe

69.30M

38.00%

APAC/Other

23.71M

13.00%

業務

地區

暫無數據

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

其他

67.25%

持股股東

佔比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

其他

67.25%

股東類型

持股股東

佔比

Investment Advisor

54.39%

Investment Advisor/Hedge Fund

25.75%

Hedge Fund

12.98%

Individual Investor

6.38%

Research Firm

2.41%

Pension Fund

2.37%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1008

55.75M

99.10%

-5.55M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

5.07M

9%

-2.87K

-0.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.71M

8.37%

-180.36K

-3.69%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.43M

6.1%

-3.13M

-47.69%

Aug 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Point72 Asset Management, L.P.

1.91M

3.4%

+796.75K

+71.36%

Jun 30, 2025

State Street Investment Management (US)

1.62M

2.88%

-66.31K

-3.93%

Jun 30, 2025

Champlain Investment Partners, LLC

1.40M

2.49%

-62.91K

-4.30%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.36M

2.43%

+842.96K

+161.67%

Jun 30, 2025

Sands Capital Management, LLC

1.25M

2.22%

-43.11K

-3.33%

Jun 30, 2025

Invesco Advisers, Inc.

1.25M

2.22%

-348.59K

-21.85%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

First Trust NYSE Arca Biotechnology Index Fund

3.05%

Invesco Biotechnology & Genome ETF

2.57%

Congress SMid Growth ETF

1.97%

iShares Health Innovation Active ETF

1.52%

VanEck Biotech ETF

1.27%

Franklin Genomic Advancements ETF

0.98%

WisdomTree BioRevolution Fund

0.98%

Pacer US Export Leaders ETF

0.87%

iShares Biotechnology ETF

0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

0.5%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.05%

Invesco Biotechnology & Genome ETF

佔比2.57%

Congress SMid Growth ETF

佔比1.97%

iShares Health Innovation Active ETF

佔比1.52%

VanEck Biotech ETF

佔比1.27%

Franklin Genomic Advancements ETF

佔比0.98%

WisdomTree BioRevolution Fund

佔比0.98%

Pacer US Export Leaders ETF

佔比0.87%

iShares Biotechnology ETF

佔比0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比0.5%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據